Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study suggests that berberine may offer multiple benefits for women with polycystic ovary syndrome by improving metabolic and hormonal profiles, though further research is needed on its long-term effects on reproductive outcomes.

In this study, oral dienogest combined with ethinylestradiol provided effective contraception with a Pearl Index of approximately 0.2 and improved androgenic symptoms without significant metabolic effects.

This review discusses the evolution of Cereblon ligands in PROTAC technology, highlighting chemical innovations that may enhance drug-likeness and applicability in protein degradation, while noting challenges and future research directions.

This protocol outlines a planned Cochrane Review to evaluate the effects of 5-alpha-reductase inhibitors on lower urinary tract symptoms caused by benign prostatic obstruction, and it reports no new findings.

This study found that treatment with oral contraceptives containing 35mg ethinylestradiol and 2mg cyproterone acetate significantly reduced serum AMH levels in women with clomiphene citrate-resistant polycystic ovary syndrome, unlike metformin.

In this review, the authors highlight the FDA approval of Ritlecitinib, the first oral treatment specifically for moderate to severe alopecia areata in patients aged 12 and older, marking a significant advancement in managing this condition.

This abstract lists keywords related to various medications and therapies, but it does not provide new study results or findings.

This study found that targeting RARβ and RXRA with CANA, in combination with MPA, could help overcome progestin resistance by restoring BAX levels and downregulating CRABP2, suggesting a novel strategy for improving clinical efficacy in this context.

In a randomized phase 2b clinical trial, oral ritlecitinib significantly reduced facial vitiligo area scores in patients with active nonsegmental vitiligo compared to placebo, with a favorable safety profile observed over 48 weeks, suggesting its potential as an effective treatment option (Ezzedine et al., 2023).

This narrative review found that ritlecitinib shows consistent effectiveness and a favorable safety profile for treating alopecia areata in clinical trials and real-world settings, with progressive hair regrowth observed, particularly when treatment is initiated early and maintained appropriately.

In this open-label study of post-menopausal women with frontal fibrosing alopecia, researchers found that 12 weeks of baricitinib monotherapy significantly reduced disease activity as measured by the Lichen Planopilaris Activity Index, improved patient-reported scalp hair growth, but showed no significant change in eyebrow growth.

Hair loss can occur as a side effect of certain breast cancer treatments, but minoxidil can help regrow hair.

This review discusses the use of acarbose for managing polycystic ovary syndrome and notes positive but limited evidence from small trials, indicating a need for more rigorous studies.

This review provides insights and guidelines for clinicians and patients on assessing the risks and benefits of ritlecitinib for adolescents with alopecia areata, emphasizing shared decision-making and management strategies.

In this study, researchers found that niosomes, bilosomes, and spanlastic formulations can enhance the oral anticoagulation efficiency of rivaroxaban in rats, with spanlastic ranked as the most effective in prolonging clotting, prothrombin, and tail bleeding times compared to unprocessed rivaroxaban.

This presentation highlighted future directions in acne care, emphasizing the roles of topical and oral antibiotics, as well as skin microbiome studies. It also described how clascoterone targets androgen receptors in hair follicles and sebaceous glands to reduce sebum production.

Ethinylestradiol/Chlormadinone Acetate is a safe and effective birth control pill that also helps regulate menstrual cycles, reduces period pain, and treats certain skin and hair conditions.

This review assesses whether using letrozole alongside physical activity and nutrition is clinically beneficial for enhancing ovulation outcomes in women with PCOS-related infertility, but it doesn't report specific results from the evaluation.

Ritlecitinib helps regrow hair in alopecia areata and is safe for long-term use.

Results are not reported in this abstract, which notes that while Janus kinase inhibitors like baricitinib show therapeutic benefits for alopecia areata, the mechanisms and reliable predictors of response remain unclear.

This study found that the antiviral drug daclatasvir significantly improved fibrosis and quality of life in a mouse model of recessive dystrophic epidermolysis bullosa, suggesting potential for treating this and other fibrotic diseases.

In this study, Buserelin nasal spray significantly reduced hirsutism scores and suppressed ovarian steroid secretion in women with non-adrenal hirsutism over six months, with effects lasting post-treatment.

This review focuses on coumarin analogs with potential antibreast cancer activities but reports no new clinical results, highlighting their mechanisms of action and structure-activity relationships.

This study reported that high-dose mizoribin therapy may be effective and safe for managing steroid-dependent pediatric systemic lupus erythematosus but requires monitoring of serum uric acid levels due to potential side effects.

This study found that Ritlecitinib significantly reduced hair loss in patients with alopecia areata by lowering SALT scores at weeks 12 and 24 compared to placebo, with acceptable safety but increased minor side effects like headaches and acne.

This article discusses the role of insulin resistance in cardiovascular risk and suggests that lifestyle changes may be more beneficial than metformin in managing polycystic ovary syndrome; it reports no new clinical results.